Status:

COMPLETED

Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants

Lead Sponsor:

AbbVie

Conditions:

Healthy Volunteers

Eligibility:

All Genders

18-60 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to compare the bioavailability of two different formulations of lutikizumab, and to assess adverse events (AEs) and how lutikizumab moves through the body in healthy Chine...

Eligibility Criteria

Inclusion

  • Male and female healthy volunteers aged between 18 and 60 years.
  • \-- Part 2 only: Participant must be first-generation Han Chinese of full Chinese parentage residing outside of China. Participant must maintain a typical Chinese lifestyle, including consuming a typical Chinese diet.
  • BMI \<= 18.0 to \<= 29.9 kg/m\^2 after rounding to the tenths decimal, at screening and upon initial confinement.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and 12-lead electrocardiogram (ECG).

Exclusion

  • Use any medications, vitamins, and/or herbal supplements within the 2 week period or 5 half-lives (whichever is longer) prior to study drug administration.
  • History of: epilepsy, any clinically significant cardiac, respiratory (except mild asthma), renal, hepatic ,gastrointestinal, hematologic, demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease, glaucoma, psychiatric disease or disorder, or any uncontrolled medical illness.
  • Prior exposure to lutikizumab.

Key Trial Info

Start Date :

September 28 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 26 2024

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT06067568

Start Date

September 28 2023

End Date

February 26 2024

Last Update

March 15 2024

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Altasciences Clinical Los Angeles, Inc /ID# 260986

Cypress, California, United States, 90630

2

Acpru /Id# 259029

Grayslake, Illinois, United States, 60030

3

PPD Clinical Research Unit - Austin /ID# 260141

Austin, Texas, United States, 78744